Article
Ease In Our Time
Ease In Our Time
By Micael Every, Global Strategist at Rabobank
Yesterday saw the BOJ hike rates to 1%, the highest level since 1995, and the RBA hold at 4.35%, with some chatter of the next move being down, not up, despite inflation running way above 2%. Today it’s the turn of new Fed Chair Warsh who, like the other central banks, has to deal with a geopolitical backdrop which may or may not allow for any monetary policy easing.
There, the text of the 14-point US-Iran MoU has been leaked ahead...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Aug 8, 2026 / Tyler Durden
Iran's Economy Is In Shambles As War Takes Its Toll
Iran's Economy Is In Shambles As War Takes Its Toll
Despite the bluster from Iranian officials on social media, it should come as no surprise that the country is not doing well economically. From the beginning of the conflict to current day, Iran has been dealt an estimated $270 billion to $300 billion in total damage due to a steady barrage of strikes, including numerous infrastructure targets from bridges, highways, railways, airports, etc.
The three-month-long US blockade on Iran's oil exports have also taken a toll, with national oil output dropping...
Read more
Sep 23, 2026 / Dave DeCamp
Israeli Attacks Kill Five Palestinians Across Gaza
Israeli forces launched attacks across Gaza on Wednesday, killing at least five Palestinians, according to reports from the Strip, as the IDF continues its constant violations of the US-backed ceasefire deal. Medical sources told Reuters that an Israeli airstrike hit a vehicle west of Khan Younis, killing two Palestinians, identified as Osama Abu Khater and […]
Read more
Oct 1, 2026 / Tyler Durden
Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics
Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics
Eli Lilly's experimental combination of eloralintide and Mounjaro delivered average weight loss of up to 23% in people with diabetes, strengthening the company's competitive edge against Novo Nordisk in the obesity and diabetes treatment market.
Participants who received the highest dose lost an average of 54 pounds over 48 weeks. Their A1C, a measure of average blood sugar, fell 2.9 percentage points from a baseline of 8.1%, with up to three-quarters reaching normal blood sugar levels, according to Bloomberg.
"This...
Read more




